Bausch + Lomb is moving beyond eye-care products with an AI platform built around the patient journey
Bausch + Lomb’s Orphia brings AI to cataract education, but adoption will depend on workflow integration, validation, privacy and trust.
Medical Devices & Diagnostics
Pharma & Biotech
Biocon’s Yesafili has FDA approval, but these new switching results may decide whether eye specialists embrace it
Biocon’s new Yesafili studies add switching and subgroup evidence ahead of a planned U.S. launch in the competitive aflibercept market.
Pharma & Biotech
Why Bausch + Lomb stopped its BL1107 neuroprotective glaucoma eye-drop program
Bausch + Lomb is dropping BL1107 eye drops after a Phase 2 glaucoma miss and redirecting the asset toward a geographic atrophy implant.
Medical Devices & Diagnostics
What iHealthScreen’s iPredict-DR clearance changes for diabetes clinics and primary care
iHealthScreen Inc. has received U.S. Food and Drug Administration 510(k) clearance for iPredict-DR, an AI-powered Software as a Medical Device for automated diabetic retinopathy screening. The retinal imaging software detects more than mild diabetic retinopathy in adults with diabetes who have not previously been diagnosed with the condition, placing the healthcare AI developer into a
Pharma & Biotech
Could OKYO Pharma’s urcosimod finally crack a painful eye disease with no approved therapy?
OKYO Pharma’s urcosimod moves toward Phase 3 as the biotech targets neuropathic corneal pain, a severe ocular condition without approved therapy.
Pharma & Biotech
Glaukos completes enrollment in GLK-321 trial as Demodex therapy competition grows
Discover how Glaukos’ GLK-321 Phase 2 trial could reshape Demodex blepharitis care through a dropless eyelid-applied treatment.
Pharma & Biotech
Can Saptalis Pharmaceuticals strengthen dry eye access with cyclosporine launch?
Find out how Saptalis Pharmaceuticals’ cyclosporine launch could reshape access, competition and generic dry eye treatment.
Pharma & Biotech
Can Minghui Pharmaceutical’s MHB018A challenge established thyroid eye disease therapies?
Find out how Minghui Pharmaceutical’s MHB018A could reshape thyroid eye disease treatment as Phase III trials test its promise.
Medical Devices & Diagnostics
Could ZEISS’s new toric intraocular lens improve predictability in astigmatism correction?
Find out how ZEISS’s AT LUCIA toric 721P lens could improve cataract surgery precision and astigmatism correction.
Pharma & Biotech
Can Samsung Bioepis reshape Europe’s retinal disease biosimilar market with OPUVIZ?
Find out how Samsung Bioepis’ OPUVIZ launch could reshape Europe’s aflibercept biosimilar market and ophthalmology access.